Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need.
We have an experienced team that has advanced multiple product candidates in parallel that focus on a range of debilitating diseases with significant unmet medical need. We continue to explore expanding our pipeline in order to develop life-changing medicines for patients who need it most.
We are focused on hiring and retaining a highly skilled team that has extensive experience and specific skill sets relating to the selection, development, and commercialization of transformative therapies. Whether in development, research, manufacturing, technical operations, or general / administrative functions, we depend on a brilliant team to support our mission of building a global, generational company.
Our benefits are competitive, and we offer dynamic career opportunities across our organization fostering a culture that embraces passion and rapid execution.
We have an experienced team that has advanced multiple product candidates in parallel that focus on a range of debilitating diseases with significant unmet medical need. We continue to explore expanding our pipeline in order to develop life-changing medicines for patients who need it most.
We are focused on hiring and retaining a highly skilled team that has extensive experience and specific skill sets relating to the selection, development, and commercialization of transformative therapies. Whether in development, research, manufacturing, technical operations, or general / administrative functions, we depend on a brilliant team to support our mission of building a global, generational company.
Our benefits are competitive, and we offer dynamic career opportunities across our organization fostering a culture that embraces passion and rapid execution.
Location: United States, Massachusetts, Lexington
Employees: 201-500
Founded date: 2015
Investors 2
| Date | Name | Website |
| - | Foresite C... | foresiteca... |
| - | Sofinnova ... | sofinnova.... |
Mentions in press and media 11
| Date | Title | Description |
| 17.07.2023 | Kiniksa Pharmaceuticals to Report Second Quarter 2023 Financial Results on July 25, 2023 | /EIN News/ -- HAMILTON, Bermuda, July 17, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 25, 2023 at 8:30 a.m. Eastern Time to repo... |
| 06.06.2023 | Kiniksa Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference | /EIN News/ -- HAMILTON, Bermuda, June 06, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conferenc... |
| 27.02.2023 | Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on February 28, 2023 | /EIN News/ -- HAMILTON, Bermuda, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 28, 2023, at 8:30 a.m. Eastern Time to... |
| 31.10.2022 | Kiniksa Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 1, 2022 | /EIN News/ -- HAMILTON, Bermuda, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, November 1, 2022, at 8:30 a.m. Eastern Time to ... |
| 03.08.2022 | Kiniksa Pharmaceuticals to Present at 2022 Wedbush PacGrow Healthcare Conference | HAMILTON, Bermuda, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that its management will participate in a fireside chat at the 2022 Wedbush PacGrow Healthcare Conference on Tuesday, August 9... |
| 18.02.2022 | Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results on February 22, 2022 | HAMILTON, Bermuda, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 22, 2022, at 8:30 a.m. Eastern Time to report its fo... |
| 03.01.2022 | Kiniksa Pharmaceuticals to Present at 40th Annual J.P. Morgan Healthcare Conference | HAMILTON, Bermuda, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 1:30 p.m. Eastern Tim... |
| 28.12.2021 | Kiniksa Announces Results from Phase 3 Trial of Mavrilimumab in COVID-19-Related ARDS | HAMILTON, Bermuda, Dec. 28, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a portfolio of assets designed to modulate immunological pathways across a spectrum of diseases,... |
| 23.11.2021 | Kiniksa Pharmaceuticals to Present at Evercore ISI 4th Annual HealthCONx Conference | HAMILTON, Bermuda, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Conference on Tuesday, November ... |
| 12.04.2021 | KINIKSA PHARMACEUTICALS, LTD. Kiniksa Announces Positive Results for Mavrilimumab Phase 2 Trial in Non-Mechanically Ventilated Severe COVID-19 Patients | – Primary endpoint achieved: the proportion of patients alive and free of mechanical ventilation at Day 29 was 12.3 percentage points higher with mavrilimumab versus placebo (p=0.1224 met predefined statistical threshold of p |
Show more